Lifitegrast ophthalmic solution
Treatment for Dry Eye Disease
Typical Dosage: One drop twice daily in each eye
Effectiveness
83%
Safety Score
75%
Clinical Trials
29
Participants
6K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
75
DangerousModerateSafe
Treatment Details
Dosage Range
One drop twice daily in each eye
Time to Effect
2-4 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$9,000
Monitoring:$600
Side Effect Mgmt:$50
Total Annual:$9,650
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$110,000/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$16,083
Cost per Remission
$48,250
Comparison vs Artificial Tears
Cost Difference
+$9,050/year
More expensive
QALY Difference
+0.06 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$6,570
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$300/year
Time Cost
$90/year
Travel + wait time
Insurance Admin Cost
$80/year
Prior auth, claims
Rx Price
$9,000/year
Potential OTC Price
$800/year
Estimated if OTC available
Early Treatment Benefit
+0.02 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWActive Clinical Trials
3 active trials recruiting for Lifitegrast ophthalmic solution in Dry Eye Disease
Clinical Evaluation of Lifitegrast Ophthalmic Solution 5.0% in Dry Eye Disease Using In Vivo Confocal Microscopy
NCT07560735NOT YET RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Nashville, United States
Started: Apr 1, 2026
Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease
NCT06879782RECRUITINGPHASE3
820 participants
INTERVENTIONAL
Beijing, China
Started: Mar 28, 2024
This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye
NCT07490535NOT YET RECRUITINGPHASE4
36 participants
INTERVENTIONAL
Sewickley, United States
Started: Mar 1, 2026
Completed Clinical Trials
10 completed trials for Lifitegrast ophthalmic solution in Dry Eye Disease
A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
NCT07025811COMPLETEDPHASE4
378 participants
INTERVENTIONAL
Newport Beach, United States +7 more
Started: Jul 9, 2025
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
NCT05505292COMPLETEDPHASE4
32 participants
INTERVENTIONAL
New York, United States
Started: Sep 22, 2022
The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study
NCT04669561COMPLETEDPHASE4
100 participants
INTERVENTIONAL
Laguna Hills, United States +2 more
Started: Mar 17, 2021
Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms
NCT03451396COMPLETEDPHASE4
30 participants
INTERVENTIONAL
Chesterfield, United States
Started: Dec 12, 2016
An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber
NCT05102409COMPLETEDPHASE2
56 participants
INTERVENTIONAL
Mississauga, Canada
Started: Sep 9, 2021
A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye
NCT01743729COMPLETEDPHASE3
720 participants
INTERVENTIONAL
Artesia, United States +30 more
Started: Dec 7, 2012
A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)
NCT00926185COMPLETEDPHASE2
230 participants
INTERVENTIONAL
Waterbury, United States +4 more
Started: Aug 3, 2009
The Effect Of Lifitegrast On Refractive Accuracy And Symptoms In Dry Eye Patients Undergoing Cataract Surgery
NCT03866629COMPLETED
103 participants
OBSERVATIONAL
Laguna Hills, United States
Started: Dec 20, 2018
A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
NCT04030962COMPLETEDPHASE1, PHASE2
292 participants
INTERVENTIONAL
Phoenix, United States +10 more
Started: Mar 4, 2020
Safety Study of Lifitegrast to Treat Dry Eye
NCT01636206COMPLETEDPHASE3
332 participants
INTERVENTIONAL
Artesia, United States +22 more
Started: Oct 16, 2012
Showing 20 of 31 total trials